Patient-Friendly Explanation
Lorcaserin, sold under the brand name Belviq, was a prescription weight-loss medication that helped patients feel fuller after eating smaller portions. It worked by targeting serotonin receptors in the brain that regulate appetite. Lorcaserin was voluntarily withdrawn from the market in 2020 after a long-term safety study raised concerns about a potential increased risk of cancer, though the absolute risk was small.
Clinical Definition
Lorcaserin is a selective serotonin 2C (5-HT2C) receptor agonist that was FDA-approved in 2012 for chronic weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity. It activated 5-HT2C receptors on anorexigenic pro-opiomelanocortin (POMC) neurons in the hypothalamus, promoting satiety and reducing food intake. The drug was withdrawn in February 2020 following the CAMELLIA-TIMI 61 trial, which showed a numerical imbalance in cancer diagnoses (7.7% vs 7.1% placebo) over a median 3.3-year follow-up, though a causal link was not definitively established.
Why It Matters
While lorcaserin is no longer available, its development highlighted the importance of long-term safety monitoring for weight-loss medications. Today, NuLifeCare prescribes newer, better-studied medications such as GLP-1 receptor agonists that have demonstrated both weight-loss efficacy and cardiovascular safety in large clinical trials.